Key result
Molecular genetic testing can identify mutations responsible for hypertrophic cardiomyopathy prior to the development of myocardial hypertrophy, aiding in screening relatives and prenatal diagnosis.
Answers are grounded in this paper and cite their sources.
Molecular genetic testing is currently most useful for screening relatives of HCM patients and for prenatal diagnosis, while its utility for sudden cardiac death risk stratification is still being evaluated.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Čurila et al. (2007) conducted a review in Hypertrophic cardiomyopathy. Molecular genetic testing was evaluated. Molecular genetic testing can identify mutations responsible for hypertrophic cardiomyopathy prior to the development of myocardial hypertrophy, aiding in screening relatives and prenatal diagnosis.
Synapse has enriched 10 related papers. Consider them for comparative context: